To hear about similar clinical trials, please enter your email below
Trial Title:
Carotid Plaque Burden in Patients With Philadelphia Negative Myeloproliferative Neoplasms
NCT ID:
NCT05993052
Condition:
Myeloproliferative Neoplasm
Conditions: Official terms:
Neoplasms
Myeloproliferative Disorders
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Cross-Sectional
Summary:
In around 90% of the patients with MPNs, an acquired mutation that promotes JAK/STAT
signaling is identified [3, 4]. The JAK/STAT pathway transduces signals from cytokines
including erythropoietin, thrombopoietin, and granulocyte colony-stimulating factor.24 A
point mutation that activates JAK2, JAK2V617F, is present in around 95% of patients with
PV and 40% to 60% of patients with ET and MF
Detailed description:
All patients will be subjected to a thorough assessment of history, complete clinical
examination, and investigations as complete blood picture including neutrophil-lymphocyte
ratio which will be analyzed with automated blood count analyzers, serum uric acid, serum
creatinine and lipid profile. All patients will undergo carotid imaging using Colour
Doppler ultrasonography for assessment of carotid plaque burden.
The control group will undergo carotid ultrasonography who will be recruited among
apparently healthy volunteers aiming to match the patient group regarding age, sex and
classical risk factors for atherosclerosis as arterial hypertension, hyperlipidemia,
diabetes, smoking or obesity.
Criteria for eligibility:
Study pop:
patients with Philadelphia negative myeloproliferative neoplasms who were diagnosed
according to the WHO 2016 criteria, at Sohag university hospital, department of internal
medicine, hematology unit and hematology outpatient clinic.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- All patients aged 18 years and older who were newly diagnosed to have Philadelphia
negative myeloproliferative neoplasms between September 2014 and November 2022 at
Sohag university hospital, department of internal medicine, hematology unit and
hematology outpatient clinic.
Exclusion Criteria:
- Patients were excluded if: (1) their disease of thrombocytosis or polycythemia was
determined to be reactive, (2) their disease was not newly diagnosed, (3) their
disease met WHO criteria for chronic or acute myeloid leukemia.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
Faculty of Medicine
Address:
City:
Sohag
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Mahmoud Gaber
Phone:
+201007399833
Email:
mahmoudgaber@med.sohag.edu.eg
Start date:
December 15, 2022
Completion date:
September 2023
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05993052
